Literature DB >> 9358496

Radiofrequency ablation of a posteroseptal accessory pathway via the middle cardiac vein in a six-year-old child.

B K O'Connor1, C L Case, P C Gillette.   

Abstract

Although radiofrequency ablation is highly successful in patients with the Wolff-Parkinson-White syndrome, certain pathways remain refractory to ablation. In particular, subepicardial pathways often fail ablation via an endocardial approach. In adult patients, left-sided subepicardial pathways have been treated successfully using energy delivery within the coronary sinus. To document the safety and efficacy of this approach in children, we present the case of a 6-year-old boy who underwent radiofrequency ablation of a posteroseptal pathway via energy delivery within the middle cardiac vein. Follow-up study showed no evidence of recurrence or gross coronary vascular injury.

Entities:  

Mesh:

Year:  1997        PMID: 9358496     DOI: 10.1111/j.1540-8159.1997.tb06094.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  3 in total

1.  Detection of inadvertent catheter movement into the coronary sinus ostium or middle cardiac vein by real-time impedance monitoring prior to radiofrequency ablation in the right atrial posteroseptal region.

Authors:  Scott J Pollak; Heather Seckel; Joseph Monir; George Ebra; George Monir
Journal:  J Interv Card Electrophysiol       Date:  2012-03-21       Impact factor: 1.900

2.  A permanent junctional reciprocating tachycardia with an atypically located accessory pathway successfully ablated from within the middle cardiac vein.

Authors:  Basri Amasyali; Sedat Kose; Kudret Aytemir; Ayhan Kilic; Hurkan Kursaklioglu; Ersoy Isik
Journal:  Heart Vessels       Date:  2006-05       Impact factor: 2.037

3.  Radiofrequency ablation of accessory pathways in children with complex congenital cardiac lesions: a report of three cases.

Authors:  Mohammad Dalili; Jayakeerthi Y Rao; Pedro Brugada
Journal:  J Tehran Heart Cent       Date:  2013-04-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.